The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Viralgen accelerates clinical development process: scaling manufacturing and completing GMP production of Trogenix's AAV gene therapy in under 12 months. SAN SEBASTIÁN, May 6, 2025 /PRNewswire ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

A research team at the University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene therapy.

Innovations in high-yield AAV production, in-process analytics, and targeted capsid design aim to make gene therapy affordable HOUSTON, May 12, 2025 /PRNewswire/ -- PackGene Biotech, Inc ...

Fractyl Health will leverage Forge’s FUEL™ platform to manufacture AAV for Rejuva, Fractyl’s pancreatic gene therapy platform for patients with obesity and type 2 diabetes Forge Biologics ...

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are ...

This in silico approach aims to increase the fitness of clinical adeno-associated virus (AAV) capsids to make gene therapies more economically viable for patients. Click here to read the article now.